Back to Search
Start Over
Advances in the Diagnosis and Treatment of a Driving Target: RET Rearrangements in non-Small-Cell Lung Cancer (NSCLC) Especially in China
- Source :
- Technology in Cancer Research & Treatment, Vol 22 (2023)
- Publication Year :
- 2023
- Publisher :
- SAGE Publishing, 2023.
-
Abstract
- In the era of precision medicine, with the deepening of the research on malignant tumor driving genes, clinical oncology has fully entered the era of targeted therapy. For non-small-cell lung cancer (NSCLC), the development of targeted drugs targeting driver genes, such as epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK), has successfully opened up a new model of targeted therapy. At present, proto-oncogene rearranged during transfection (RET) fusion gene is an important novel oncogenic driving target, and specific receptor tyrosine kinase inhibitors (TKIs) targeting RET fusion have been approved. This article will review the latest research about the molecular characteristics, pathogenesis, detection, and clinical treatment strategies of RET rearrangements especially in China.
- Subjects :
- Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Subjects
Details
- Language :
- English
- ISSN :
- 15330338
- Volume :
- 22
- Database :
- Directory of Open Access Journals
- Journal :
- Technology in Cancer Research & Treatment
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.b98c611e6ec8423ca993bee8a7ce04e1
- Document Type :
- article
- Full Text :
- https://doi.org/10.1177/15330338221148802